Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
benzinga.com/general/biotech/25/05/45145598/moderna-expands-cost-cutting-program-by-up-to-17-billion-fda-approval-for-flucovid-19-combo-shot-
Moderna Inc. (NASDAQ:MRNA) reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.
The COVID-19 vaccine maker reported quarterly sales of $108 million, down from $167 billion a year ago, beating the…
This story appeared on benzinga.com, 2025-05-01 17:14:38.